286372-29-0

Upstream product

• 286372-20-1 8-(tert-butyl-dimethyl-silanyloxy)-1-(tert-butyl-diphenyl-silanyloxy)-3,5-dimethyl-6-trimethylsilanyloxy-oct-2-en-4-ol 
• 286372-22-3 (4S,5S,6R)-4-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-6-[(Z)-3-(tert-butyl-diphenyl-silanyloxy)-1-methyl-propenyl]-2,2,5-trimethyl-[1,3]dioxane 
• 286372-21-2 (Z)-(3S,4S,5R)-1-(tert-Butyl-dimethyl-silanyloxy)-8-(tert-butyl-diphenyl-silanyloxy)-4,6-dimethyl-oct-6-ene-3,5-diol 
• 251089-75-5 toluene-4-sulfonic acid 6-benzyloxycarbonylamino-7-methoxy-3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-8-ylmethyl ester 
• 286372-48-3 1-(tert-butyl-dimethyl-silanyloxy)-8-(tert-butyl-diphenyl-silanyloxy)-4,6-dimethyl-oct-6-ene-3,5-diol 
• 251089-63-1 8-(tert-butyl-dimethyl-silanyloxy)-1-(tert-butyl-diphenyl-silanyloxy)-6-hydroxy-3,5-dimethyl-oct-2-en-4-one 
• 251089-60-8 (8-benzenesulfonylmethyl-7-methoxy-3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)-carbamic acid benzyl ester 
• 286372-25-6 6-benzyloxycarbonylamino-7-methoxy-3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-8-carboxylic acid methyl ester 
• 251089-74-4 (8-hydroxymethyl-7-methoxy-3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)-carbamic acid benzyl ester 
• 251089-76-6 6-amino-8-benzenesulfonylmethyl-7-hydroxy-4H-benzo[1,4]thiazin-3-one 
• 286372-23-4 2-methoxy-6-methoxycarbonylmethylsulfanyl-3,5-dinitro-benzoic acid methyl ester 
• 286372-24-5 6-amino-7-methoxy-3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-8-carboxylic acid methyl ester 
• 251089-79-9 (3R,4S)-6-(tert-Butyl-dimethyl-silanyloxy)-3-methyl-4-trimethylsilanyloxy-hex-1-ene 
• 251089-58-4 2-fluoro-6-methoxy-3,5-dinitro-benzoic acid methyl ester 

Relevant academic research and scientific papers

Total synthesis of the ansamycin antibiotic (+)-thiazinotrienomycin E

The first total synthesis of (+)-thiazinotrienomycin E (1), member of a novel class of cytotoxic ansamycin antibiotics, has been achieved. Key features of the synthetic strategy include (a) the efficient construction of sulfone 7 incorporating TBS protection of the aniline, (b) an improved synthesis of allyl chloride (-)-6, the advanced intermediate employed in our trienomycins A and F total syntheses, (c) application of the Kocienski modified Julia protocol to elaborate the E,E,E-triene subunit in a stereo- controlled fashion, (d) an efficient union of sulfone 7 with advanced iodide 62, and (e) Mukaiyama macrolactamization to access the thiazinotrienomycin macrocyclic ring.